NCT00735020

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines

A Phase I, Observer-Blind, Randomized, Single-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines in Healthy Adults Aged 18 to 39 Years.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 18 Years – 39 Years
• Healthy volunteers: Accepted

Summary

This trial is designed to evaluate safety, tolerability and immunogenicity of a bedside mixing formulation of adjuvanted influenza vaccines.

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Adjuvanted Influenza Vaccine	1 dose of Adjuvanted Influenza Vaccine
BIOLOGICAL	Influenza Vaccine	1 dose of Influenza Vaccine

Timeline

• Start date: 2008-06-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2008-08-14
• Last updated: 2014-01-24

Locations

1 site across 1 country: Switzerland